CELLINK AB – CELLINK, or The Company – has been awarded funding, alongside partners. Their share is placed at around €350,000, where Horizon 2020 accounts for 100% of the financial support.

CELLINK has been awarded funding from the EU for the project SilkFUSION – genetically engineered human pluriopotent stem cells, functionalised silk-fibroin platforms and bio-inks, of which is a novel solution for large-scale ex-vivo platelet production, transfusion and drug research.

Alongside six partners, CELLINK received funding for the project at 100% of the project’s estimated total cost, around €3m.

The project is scheduled to endure for 48 months, and the company does not incur any costs for the project.

The company’s bioink is currently used by research institutions worldwide, however the project aims to develop new Bioink for this specific application.

CELLINK’s universal Bioink can currently be used through CELLINK’s proprietary 3D Bioprinters, as well as those developed by other operators.

The post CELLINK granted funding from Horizon 2020 appeared first on Horizon 2020 Projects.